Latest News about CYBN
Recent news which mentions CYBN
Psychedelic Stock Gainers And Losers From July 7, 2022
July 07, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From July 6, 2022
July 06, 2022
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From July 1, 2022
July 01, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 30, 2022
June 30, 2022
From Benzinga
From Benzinga
From Benzinga
Cybin's Psilocybin Analog CYB003 Gets FDA Clearance For Trial To Potentially Treat Major Depressive Disorder
June 28, 2022
Tickers
CYBN
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From June 22, 2022
June 22, 2022
From Benzinga
10 Psychedelics CEOs To Pay Attention To In 2022
June 22, 2022
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From June 17, 2022
June 17, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 16, 2022
June 16, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 15, 2022
June 15, 2022
From Benzinga
Psyched: Elon Musk Tweets About Psychedelics, Numinus Acquires Novamind, Colorado Gov. Signs MDMA Legalization Bill
June 15, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From June 14, 2022
June 14, 2022
From Benzinga
From Benzinga
From InvestorPlace
Cybin Moves Forward With Phase 1/2a Clinical Trial For Treatment Of Major Depressive Disorder
June 10, 2022
Tickers
CYBN
From Benzinga
Psychedelic Stock Gainers And Losers From June 10, 2022
June 10, 2022
From Benzinga
Elon Musk Says Psychedelics Should Be Seriously Considered For Therapeutic Uses, Leading Chorus Of Celeb Support
June 10, 2022
From Benzinga
From InvestorPlace
From Benzinga
From Benzinga
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.